15357163mct170200-sup-179899_3_supp_4462166_p182wf.pptx (635.04 kB)
Figures S1-S3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
figure
posted on 2023-04-03, 15:09 authored by Michael D. Oberst, Catherine Augé, Chad Morris, Stacy Kentner, Kathy Mulgrew, Kelly McGlinchey, James Hair, Shino Hanabuchi, Qun Du, Melissa Damschroder, Hui Feng, Steven Eck, Nicholas Buss, Lolke de Haan, Andrew J. Pierce, Haesun Park, Andrew Sylwester, Michael K. Axthelm, Louis Picker, Nicholas P. Morris, Andrew Weinberg, Scott A. HammondSupplementary Figure 1. Immunophenotype of CD4 T effector (Teff) and regulatory (Treg) cells used in Teff/Treg co-cultures. ( Supplementary Figure 2. Flow cytometry panels and gating strategy for analysis of rhesus peripheral T cells. Supplementary Figure 3. Binding of MEDI6383 to OX40 expressing human and NHP T cells. Dot plot representing the percentage of purified, live, PHA/IL-2 activated human CD4.